Publication at First Faculty of Medicine |
2010
Abstract
Febrile neutropenia in adult patiens with malignant disease More than 40 years we know the impact of absolute neutrophil count on the risk of developing infection. Through the extensive research and endless number of clinical trials we came to the treatment algorithm, which has reduced infection-related mortality to less than 10 percent.
Patients with febrile neutropenia represent very heterogenous group. Currently we are able to stratify patients into risk groups and adequately treat them.
On one hand, unstable patient profits from aggressive empirical antibiotic treatment, on the other hand, low-risk patient could be managed in outpatient settings.